January 11, 2019
Sumitomo Dainippon Pharma said on January 10 that its atypical antipsychotic Latuda (lurasidone) hit the primary endpoint in a global PIII study enrolling patients with schizophrenia, with the company now planning to file the drug in Japan by the end...read more